Drugs / StrataXRT
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03990597 | Aug 2019 → Nov 2020 | central nervous system germ cell tumor, central nervous system sarcoma, ependymoma, medulloblastoma +1 | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05073172 | Jan → Dec 2024 | breast carcinoma, head and neck carcinoma, radiodermatitis | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | StrataXRT | “StrataXRT may help prevent or decrease severe skin rash, pain, itching, skin peeling, and dry skin in pediatric patients undergoing radiation therapy.” NCT03990597 ↗1“ARM I: Patients apply StrataXRT topically to the affected area once or twice daily” NCT05073172 ↗ |
| Modality | Other / unclassified | “a silicone topical wound dressing (StrataXRT)” NCT03990597 ↗ |
| Route | Topical | “Applied StrataXRT topically” NCT03990597 ↗ |